Clark Capital Management Group Lifted Its D R Horton (DHI) Position by $7.90 Million as Share Value Declined; As Celgene (CELG) Valuation Declined, Bb Biotech Ag Cut Its Holding

August 12, 2018 - By Margaret Guttierez

D.R. Horton, Inc. (NYSE:DHI) Logo

Bb Biotech Ag decreased its stake in Celgene Corp (CELG) by 2.92% based on its latest 2018Q1 regulatory filing with the SEC. Bb Biotech Ag sold 100,000 shares as the company’s stock declined 18.51% with the market. The institutional investor held 3.32 million shares of the major pharmaceuticals company at the end of 2018Q1, valued at $296.56 million, down from 3.42 million at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $64.15B market cap company. The stock decreased 0.77% or $0.71 during the last trading session, reaching $91.21. About 3.25M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since August 12, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 23/04/2018 – European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed; 16/05/2018 – Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions; 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE; 10/04/2018 – The University of Texas MD Anderson Cancer Center and Nanobiotix Have an Agreement to Run lmmunotherapeutic Pre-Clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab; 19/04/2018 – CELGENE CORP – GILLA KAPLAN WILL NOT STAND FOR REELECTION AT UPCOMING ANNUAL MEETING OF STOCKHOLDERS; 30/05/2018 – Denali Has Chosen to Exercise Early Option to Acquire Asset-Centric Vehicle F-Star Gamma Ltd; 24/03/2018 – ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Societ; 02/04/2018 – Tis the Season for the Reason to Visit Tuolumne County’s Yosemite for Nearly 30 Days of Christmas; 04/05/2018 – CELGENE STILL OPEN TO DEALS; DOESN’T NOTE ANYTHING SPECIFIC; 05/03/2018 – Parkinson’s Institute and Clinical Center Collaborates With Denali Therapeutics to Explore New Endpoints for Clinical Studies

Clark Capital Management Group Inc increased its stake in D R Horton Inc (DHI) by 71.31% based on its latest 2018Q1 regulatory filing with the SEC. Clark Capital Management Group Inc bought 183,777 shares as the company’s stock declined 3.70% with the market. The institutional investor held 441,509 shares of the capital goods company at the end of 2018Q1, valued at $19.36M, up from 257,732 at the end of the previous reported quarter. Clark Capital Management Group Inc who had been investing in D R Horton Inc for a number of months, seems to be bullish on the $16.94B market cap company. The stock decreased 0.18% or $0.08 during the last trading session, reaching $44.92. About 3.58M shares traded. D.R. Horton, Inc. (NYSE:DHI) has risen 28.42% since August 12, 2017 and is uptrending. It has outperformed by 15.85% the S&P500.

Since February 12, 2018, it had 0 insider purchases, and 12 selling transactions for $2.08 million activity. Shares for $474,147 were sold by HORTON DONALD R. The insider Auld David V sold 4,986 shares worth $224,384. Another trade for 2,423 shares valued at $110,794 was made by Allen Barbara K on Tuesday, February 20. On Monday, March 5 WHEAT BILL W sold $109,542 worth of D.R. Horton, Inc. (NYSE:DHI) or 2,568 shares. Hewatt Michael W also sold $143,213 worth of D.R. Horton, Inc. (NYSE:DHI) on Thursday, March 1.

More recent D.R. Horton, Inc. (NYSE:DHI) news were published by: Seekingalpha.com which released: “Analysing America’s Builders” on August 06, 2018. Also Seekingalpha.com published the news titled: “Mortgage rates march higher; homebuilder stocks slump” on August 02, 2018. Benzinga.com‘s news article titled: “4 Stocks In Bullish Uptrends This Week” with publication date: July 31, 2018 was also an interesting one.

Investors sentiment decreased to 0.97 in Q1 2018. Its down 0.07, from 1.04 in 2017Q4. It turned negative, as 69 investors sold DHI shares while 189 reduced holdings. 81 funds opened positions while 169 raised stakes. 306.71 million shares or 0.84% more from 304.15 million shares in 2017Q4 were reported. Highland Cap Management Lp has invested 0.1% of its portfolio in D.R. Horton, Inc. (NYSE:DHI). 29.95 million are owned by Blackrock Incorporated. Hsbc Pcl invested in 0.05% or 776,157 shares. Cipher Capital Lp accumulated 0.4% or 74,703 shares. Ubs Oconnor Limited Co has 0% invested in D.R. Horton, Inc. (NYSE:DHI). Apg Asset Nv owns 461,424 shares. Banque Pictet And Cie holds 6,500 shares. Nuwave Mgmt Ltd owns 4,278 shares. Moreover, Of Oklahoma has 0% invested in D.R. Horton, Inc. (NYSE:DHI) for 6,750 shares. Wexford Limited Partnership stated it has 141,237 shares. Orrstown reported 846 shares. Metropolitan Life Insurance has invested 0% of its portfolio in D.R. Horton, Inc. (NYSE:DHI). State Of New Jersey Common Pension Fund D has 0.01% invested in D.R. Horton, Inc. (NYSE:DHI) for 80,500 shares. Point72 Asset Management Ltd Partnership holds 0.13% or 720,600 shares in its portfolio. 307,479 are held by Nuveen Asset Mgmt Limited Liability.

Clark Capital Management Group Inc, which manages about $1.95B and $3.21 billion US Long portfolio, decreased its stake in Amazon Com Inc (NASDAQ:AMZN) by 14,220 shares to 531 shares, valued at $769,000 in 2018Q1, according to the filing. It also reduced its holding in Powershares Etf Tr Ii (SPHB) by 482,110 shares in the quarter, leaving it with 805,844 shares, and cut its stake in Vanguard Tax Managed Intl Fd (VEA).

Among 25 analysts covering DR Horton Inc (NYSE:DHI), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. DR Horton Inc had 82 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, July 13 by RBC Capital Markets. The rating was maintained by Buckingham Research on Friday, November 10 with “Neutral”. The firm has “Buy” rating by Keefe Bruyette & Woods given on Monday, June 5. The firm has “Equalweight” rating by Barclays Capital given on Thursday, April 7. The firm has “Equal-Weight” rating given on Tuesday, October 13 by Barclays Capital. The firm has “Market Outperform” rating by JMP Securities given on Friday, July 27. The stock has “Neutral” rating by UBS on Monday, January 18. The firm earned “Hold” rating on Thursday, January 18 by Mizuho. Barclays Capital upgraded the shares of DHI in report on Monday, March 26 to “Overweight” rating. The firm has “Outperform” rating by Raymond James given on Friday, June 30.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on October, 25. They expect $1.99 EPS, up 11.80% or $0.21 from last year’s $1.78 per share. CELG’s profit will be $1.40B for 11.46 P/E if the $1.99 EPS becomes a reality. After $1.86 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 6.99% EPS growth.

Investors sentiment decreased to 0.79 in 2018 Q1. Its down 0.04, from 0.83 in 2017Q4. It dropped, as 120 investors sold CELG shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported. Tealwood Asset accumulated 0.54% or 15,349 shares. Missouri-based Financial Counselors Inc has invested 0.31% in Celgene Corporation (NASDAQ:CELG). Amer National Tx has 86,545 shares. Patten And Patten Tn stated it has 54,532 shares or 0.5% of all its holdings. Wellington Management Grp Inc Ltd Liability Partnership has 0.05% invested in Celgene Corporation (NASDAQ:CELG). Glenview Savings Bank Tru Dept reported 0.85% stake. State Of New Jersey Common Pension Fund D invested in 570,000 shares or 0.2% of the stock. Mercer Capital Advisers Inc reported 1,690 shares. The New Jersey-based Lucas Cap Mgmt has invested 2.59% in Celgene Corporation (NASDAQ:CELG). Cypress Asset Mngmt Tx accumulated 0.3% or 11,635 shares. Mai Capital Management holds 5,906 shares or 0.03% of its portfolio. Loring Wolcott Coolidge Fiduciary Advsr Limited Liability Partnership Ma reported 1.22 million shares. Everence Cap Mngmt Inc holds 19,103 shares or 0.38% of its portfolio. At National Bank owns 0.28% invested in Celgene Corporation (NASDAQ:CELG) for 29,226 shares. Calamos Wealth Lc holds 0.08% or 7,160 shares.

Bb Biotech Ag, which manages about $3.62B US Long portfolio, upped its stake in Ionis Pharmaceuticals Inc. by 380,000 shares to 8.52 million shares, valued at $375.40M in 2018Q1, according to the filing. It also increased its holding in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) by 60,000 shares in the quarter, for a total of 545,719 shares, and has risen its stake in Tesaro Inc. (NASDAQ:TSRO).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Investorplace.com which released: “5 Top Stock Trades for Friday — Buy Yelp, Roku After Earnings Surge?” on August 09, 2018, also Seekingalpha.com with their article: “Celgene Has Emerged As An Attractive Buy Opportunity In 2018” published on August 10, 2018, Nasdaq.com published: “Celgene (CELG) Q2 Earnings: Disappointment in Store?” on July 23, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: 247Wallst.com and their article: “Why Have Short Sellers Backed Off Major Biotechs?” published on August 10, 2018 as well as Benzinga.com‘s news article titled: “Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene” with publication date: August 09, 2018.

Since February 15, 2018, it had 1 buying transaction, and 5 selling transactions for $6.21 million activity. Shares for $851,093 were sold by LOUGHLIN JAMES J. Alles Mark J also bought $99,784 worth of Celgene Corporation (NASDAQ:CELG) on Tuesday, May 8. CASEY MICHAEL D sold $1.02M worth of stock. MARIO ERNEST also sold $1.26M worth of Celgene Corporation (NASDAQ:CELG) shares.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 21 have Buy rating, 1 Sell and 13 Hold. Therefore 60% are positive. Celgene Corporation had 153 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Monday, October 16 by Canaccord Genuity. On Friday, October 27 the stock rating was downgraded by JMP Securities to “Hold”. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 15. The stock of Celgene Corporation (NASDAQ:CELG) has “Underweight” rating given on Thursday, October 5 by Morgan Stanley. The firm has “Buy” rating by Cowen & Co given on Friday, October 20. Mizuho maintained Celgene Corporation (NASDAQ:CELG) rating on Monday, February 5. Mizuho has “Buy” rating and $128.0 target. The rating was initiated by Standpoint Research on Thursday, January 14 with “Buy”. The stock has “Neutral” rating by BTIG Research on Friday, June 30. The rating was initiated by Leerink Swann with “Market Perform” on Friday, February 5. The rating was downgraded by BTIG Research on Wednesday, June 1 to “Neutral”.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts